Waters Corporation (WAT)vsGeneDx Holdings Corp. (WGS)
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
WGS
GeneDx Holdings Corp.
$66.95
-2.50%
HEALTHCARE · Cap: $2.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 640% more annual revenue ($3.17B vs $427.54M). WAT leads profitability with a 20.3% profit margin vs -4.9%. WAT earns a higher WallStSmart Score of 60/100 (C).
WAT
Buy60
out of 100
Grade: C
WGS
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Intrinsic value data unavailable for WGS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Revenue surging 26.5% year-over-year
Areas to Watch
Moderate valuation
Earnings declined 3.1%
0.0% earnings growth
ROE of -7.6% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bull Case : WGS
The strongest argument for WGS centers on Revenue Growth. Revenue growth of 26.5% demonstrates continued momentum.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Bear Case : WGS
The primary concerns for WGS are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
WAT profiles as a mature stock while WGS is a growth play — different risk/reward profiles.
WGS carries more volatility with a beta of 2.15 — expect wider price swings.
WGS is growing revenue faster at 26.5% — sustainability is the question.
WAT generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (60/100 vs 30/100), backed by strong 20.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
GeneDx Holdings Corp.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?